News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TRACON Pharmaceuticals, Inc. Initiates Phase 1b Study Of TRC105 In Patients With Advanced Soft Tissue Sarcoma


2/4/2014 9:27:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Feb. 3, 2014 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced the initiation of dosing in a clinical trial evaluating the combination of TRC105 and Votrient® (pazopanib, GlaxoSmithKline), a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, to treat patients with advanced soft tissue sarcoma. TRC105, a novel monoclonal antibody to endoglin (CD105), is being studied in multiple clinical trials in combination with agents that target the VEGF pathway.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   
Sarcoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES